Avtal | $24,000,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Certified by Founder
Lodge
Mable | Neurolytic Healthcare
start up
United States
- San Francisco, California
- 27/07/2022
- Seed
- $3,200,000
Migraines are heritable. Uncover the link between your genetics and migraines to help prevent your migraine in advance and get medication delivered directly to your door.
- Industry Hospital & Health Care
- Website https://www.trymable.com/?utm_source=linkedin&utm_medium=social&utm_campaign=custom_button
- LinkedIn https://www.linkedin.com/company/mable-migraine-relief/
Related People
Roman RothaermelCo Founder
United Kingdom -
London, England
Before founding Mable, I was a researcher at the University of Oxford working at the intersection between neuroscience, data science and pharmacology. Today at Mable, we're using data-driven approaches to fight neurological conditions starting with migraines - a problem that affects 12% of the population and is in urgent need of innovation in care quality and delivery mechanisms.
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)